Interleukin-1 Blockade in Cardiac Sarcoidosis: A Pilot Study

Affiliations

• ¹ Virginia Commonwealth University (VCU) Pauley Heart Center (J.K., J.H.J., A.L., V.M.D., A.B., K.E., B.W.V.T., W.G.H.), Virginia Commonwealth University, Richmond.
• ² Cardiovascular Center, University of Michigan, Ann Arbor (T.C., F.B., T.K., K.B., S.L.-P.).
• ³ Department of Biomedical Engineering (J.H.J.), Virginia Commonwealth University, Richmond.
• ⁴ Division of Rheumatology, Allergy, and Immunology (H.S.), Virginia Commonwealth University, Richmond.
• ⁵ Division of Pulmonary and Critical Care (A.S., T.I., K.P., E.G.F.), Virginia Commonwealth University, Richmond.
• ⁶ Department of Medicine (Cardiology), University of Ottawa Heart Institute, Canada (A.T., R.B., D.B.).
• ⁷ Department of Pharmacotherapy and Outcomes Science (B.W.V.T.), Virginia Commonwealth University, Richmond.
• ⁸ Robert M. Berne Cardiovascular Research Center, Charlottesville, VA (A.A.).
• ⁹ Division of Cardiology, Heart and Vascular Center, University of Virginia, Charlottesville (A.A.).